LamdaGen’s nano-based Plasmonic Diagnostic Platforms enable central laboratory grade quantitation for high-sensitivity immunoassays. The platforms facilitate rapid diagnostic detection limits into the femtomolar range, more than four orders of magnitude lower than that of conventional ELISA.
LamdaGen’s nano-plasmonic LSPR films can be grown on virtually any solid support including:
- Flexible Membranes
- Stainless Steel
The Company’s plasmonic sensors are easily manufactured in any size or shape and are typically grown as individual or multi-paneled circular spots ranging in diameter from 300 microns up to 2.5 millimeters each – depending on functional density and system needs.
When coupling flexible sizing with the ability to configure sensors into any shape and upon any solid support – the diagnostic platform becomes an exceedingly adaptable and powerful system for In Vitro Diagnostic integration. Additionally, the platform offers significant multiplexing capabilities.
The multi-panel LSPR sensors can be configured to meet almost any throughput need – from multi-parallel simultaneous systems to combined multiplexed series formats that can be actively timed or sequenced over periods of minutes, hours or even days – depending on system and end user needs.
LamdaGen’s Plasmonic-based Diagnostic Platforms enable:
- Central lab and POC applications
- Femtomolar sensitivities
- Precise quantitation
- Twenty minute assay times
- Multiplex panels
- Ideal for wearable and mobile sensing applications
The Platforms provide rapid, laboratory grade sensitivity and specificity, on a range of sample types including:
LamdaGen has developed very rapid diagnostic assays demonstrating clinical level feasibility in areas such as:
- Cardiovascular Health
- Infectious Disease
- Cancer Biomarkers
- Drugs of Abuse
- Contaminant Monitoring
For data and additional information, email us at email@example.com
Troponin I (cTnI) Quantification
A sensitive biomarker of myocardial injury
Troponin I (cTnI):
- Central to the earlier diagnosis of myocardial infarction (MI)
- Prediction of outcome: death/MI and further risk
Plasmonic ELISA™ Platform Assay:
- Detect TnI at 0.64 pg/mL
- Significantly more sensitive than commercial ELISA kits
- Precise and easy quantitation